Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

522.81
-3.9200-0.74%
Post-market: 525.002.19+0.42%19:45 EDT
Volume:1.15M
Turnover:601.41M
Market Cap:132.65B
PE:30.43
High:529.72
Open:525.26
Low:522.74
Close:526.73
52wk High:560.25
52wk Low:392.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:1.29
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.55
PE(LYR):34.13

Loading ...

Vertex Pharmaceuticals Price Target Raised to $615.00/Share from $585.00 by UBS

Dow Jones
·
Sep 29

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating

MT Newswires Live
·
Sep 28

Vertex Minerals Sets October General Meeting for Shareholders

TIPRANKS
·
Sep 25

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 25

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated

TIPRANKS
·
Sep 23

Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633

THOMSON REUTERS
·
Sep 23

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Dow Jones
·
Sep 23

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

TIPRANKS
·
Sep 22

Maze jumps 25% to $27.99 after Vertex kidney disease data

TIPRANKS
·
Sep 22

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Reuters
·
Sep 22

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live
·
Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

TIPRANKS
·
Sep 22

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Reuters
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS
·
Sep 22